This page has only limited features, please log in for full access.
Bariatric surgery is the most efficacious treatment for obesity, though it is not free from complications. Preoperative conditioning has proved beneficial in various clinical contexts, but the evidence is scarce on the role of prehabilitation in bariatric surgery. We describe the protocol and pilot study of a randomized (ratio 1:1), parallel, controlled trial assessing the effect of a physical conditioning and respiratory muscle training programme, added to a standard 8-week group intervention based on therapeutical education and cognitive-behavioural therapy, in patients awaiting bariatric surgery. The primary outcome is preoperative weight-loss. Secondary outcomes include associated comorbidity, eating behaviour, physical activity, quality of life, and short-term postoperative complications. A pilot sample of 15 participants has been randomized to the intervention or control groups and their baseline features and results are described. Only 5 patients completed the group programme and returned for assessment. Measures to improve adherence will be implemented and once the COVID-19 pandemic allows, the clinical trial will start. This is the first randomized, clinical trial assessing the effect of physical and respiratory prehabilitation, added to standard group education and cognitive-behavioural intervention in obese patients on the waiting list for bariatric surgery. Clinical Trial Registration: NCT0404636.
Yaiza García-Delgado; María José López-Madrazo-Hernández; Dácil Alvarado-Martel; Guillermo Miranda-Calderín; Arantza Ugarte-Lopetegui; Raúl Alberto González-Medina; Alba Hernández-Lázaro; Garlene Zamora; Nuria Pérez-Martín; Rosa María Sánchez-Hernández; Adriana Ibarra-González; Mónica Bengoa-Dolón; Carmen Teresa Mendoza-Vega; Svein Mikael Appelvik-González; Yurena Caballero-Díaz; Juan Ramón Hernández-Hernández; Ana María Wägner. Prehabilitation for Bariatric Surgery: A Randomized, Controlled Trial Protocol and Pilot Study. Nutrients 2021, 13, 2903 .
AMA StyleYaiza García-Delgado, María José López-Madrazo-Hernández, Dácil Alvarado-Martel, Guillermo Miranda-Calderín, Arantza Ugarte-Lopetegui, Raúl Alberto González-Medina, Alba Hernández-Lázaro, Garlene Zamora, Nuria Pérez-Martín, Rosa María Sánchez-Hernández, Adriana Ibarra-González, Mónica Bengoa-Dolón, Carmen Teresa Mendoza-Vega, Svein Mikael Appelvik-González, Yurena Caballero-Díaz, Juan Ramón Hernández-Hernández, Ana María Wägner. Prehabilitation for Bariatric Surgery: A Randomized, Controlled Trial Protocol and Pilot Study. Nutrients. 2021; 13 (9):2903.
Chicago/Turabian StyleYaiza García-Delgado; María José López-Madrazo-Hernández; Dácil Alvarado-Martel; Guillermo Miranda-Calderín; Arantza Ugarte-Lopetegui; Raúl Alberto González-Medina; Alba Hernández-Lázaro; Garlene Zamora; Nuria Pérez-Martín; Rosa María Sánchez-Hernández; Adriana Ibarra-González; Mónica Bengoa-Dolón; Carmen Teresa Mendoza-Vega; Svein Mikael Appelvik-González; Yurena Caballero-Díaz; Juan Ramón Hernández-Hernández; Ana María Wägner. 2021. "Prehabilitation for Bariatric Surgery: A Randomized, Controlled Trial Protocol and Pilot Study." Nutrients 13, no. 9: 2903.
BackgroundType 1 diabetes is a disease with complex therapeutic recommendations that require day-to-day lifestyle changes. Motivational Interviewing is a communication tool that has proved effective in changing behaviors in people with addictions, obesity and type 2 diabetes. Our objective is to evaluate the effects of a Motivational Interviewing intervention in people with type 1 diabetes.MethodsSixty-six patients with type 1 diabetes and hemoglobin A1c >= 8% have been included and randomly assigned (computer-generated sequence, sealed envelopes, ratio 1:1) either to the intervention or to the control group. In the intervention group, appointments every 4 months with the endocrinologist include Motivational Interviewing; in the control group, the appointments proceed as usual. Patients will be followed for 16 months. The primary outcome will be self-care behaviors, assessed by a validated questionnaire, the Diabetes Self-Care Inventory-Revised Version. Secondary outcomes include: HbA1c, motivation for self-care, self-efficacy, health-related quality of life, satisfaction with professional-patient relationship, and fulfillment of patients’ own objectives. The practitioners receive training in Motivational Interviewing in order to help them promote adherence to self-care, encourage patient motivation and improve the doctor-patient relationship. The Motivational Interviewing intervention will be evaluated by two psychologists, blinded to the assigned treatment, through video recordings of the sessions and the administration of a purpose-built questionnaire, the EVEM 2.0 scale.DiscussionThere is evidence that MI can improve self-care in type 2 diabetes. In this study, we aim to evaluate the effect of MI on self-care and HbA1c in people with type 1 diabetes.Clinical Trial Registrationhttps://clinicaltrials.gov/ct2/show/NCT03906786, identifier NCT03906786.
Dácil Alvarado-Martel; Mauro Boronat; María Del Pino Alberiche-Ruano; María Andrea Algara-González; Yolanda Ramallo-Fariña; Ana M. Wägner. Motivational Interviewing and Self-Care in Type 1 Diabetes: A Randomized Controlled Clinical Trial Study Protocol. Frontiers in Endocrinology 2020, 11, 1 .
AMA StyleDácil Alvarado-Martel, Mauro Boronat, María Del Pino Alberiche-Ruano, María Andrea Algara-González, Yolanda Ramallo-Fariña, Ana M. Wägner. Motivational Interviewing and Self-Care in Type 1 Diabetes: A Randomized Controlled Clinical Trial Study Protocol. Frontiers in Endocrinology. 2020; 11 ():1.
Chicago/Turabian StyleDácil Alvarado-Martel; Mauro Boronat; María Del Pino Alberiche-Ruano; María Andrea Algara-González; Yolanda Ramallo-Fariña; Ana M. Wägner. 2020. "Motivational Interviewing and Self-Care in Type 1 Diabetes: A Randomized Controlled Clinical Trial Study Protocol." Frontiers in Endocrinology 11, no. : 1.
Background Type 2 diabetes mellitus (T2DM) is a chronic disease in which health outcomes are related to decision making by patients and health care professionals. Objective This study aims to assess the effectiveness of internet-based multicomponent interventions to support decision making of all actors involved in the care of patients with T2DM in primary care. Methods The INDICA study is an open, community-based, multicenter trial with random allocation to usual care or the intervention for patients, the intervention for health care professionals in primary care, or the combined intervention for both. In the intervention for patients, participants received an educational group program and were monitored and supported by logs, a web-based platform, and automated SMS. Those in the intervention for professionals also received an educational program, a decision support tool embedded in the electronic clinical record, and periodic feedback about patients’ results. A total of 2334 people with T2DM, regardless of glycated hemoglobin (HbA1c) levels and without diabetes-related complications, were included. The primary end point was change in HbA1c level. The main analysis was performed using multilevel mixed models. Results For the overall sample, the intervention for patients attained a significant mean reduction in HbA1c levels of ‒0.27 (95% CI ‒0.45 to ‒0.10) at month 3 and ‒0.26 (95% CI ‒0.44 to ‒0.08) at month 6 compared with usual care, which remained marginally significant at month 12. A clinically relevant reduction in HbA1c level was observed in 35.6% (191/537) of patients in the intervention for patients and 26.0% (152/586) of those in usual care at month 12 (P=.006). In the combined intervention, HbA1c reduction was significant until month 18 (181/557, 32.6% vs 140/586, 23.9%; P=.009). Considering the subgroup of patients uncontrolled at baseline, all interventions produced significant reductions in HbA1c levels across the entire study period: ‒0.49 (95% CI ‒0.70 to ‒0.27) for the intervention for patients, ‒0.35 (95% CI ‒0.59 to ‒0.14) for the intervention for professionals, and ‒0.35 (95% CI ‒0.57 to ‒0.13) for the combined intervention. Differences in HbA1c for the area under the curve considering the entire period were significant for the intervention for patients and the combined intervention compared with usual care (P=.03 for both). Compared with usual care, the intervention for professionals and the combined intervention had significant longer-term reductions in systolic and diastolic blood pressure. Conclusions In uncontrolled patients, the intervention for patients at baseline provided clinically relevant and significant longer-term reductions of HbA1c levels. The intervention for professionals and combined intervention also improved the cardiovascular risk profile of patients. Trial Registration ClinicalTrials.gov NCT01657227; https://clinicaltrials.gov/ct2/show/NCT01657227
Yolanda Ramallo-Fariña; Miguel Angel García-Bello; Lidia García-Pérez; Mauro Boronat; Ana M Wägner; Leticia Rodríguez-Rodríguez; Pedro De Pablos-Velasco; Ignacio Llorente Gómez De Segura; Himar González- Pacheco; Montserrat Carmona Rodríguez; Pedro Serrano-Aguilar; Indica Team. Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial. JMIR mHealth and uHealth 2020, 8, e18922 .
AMA StyleYolanda Ramallo-Fariña, Miguel Angel García-Bello, Lidia García-Pérez, Mauro Boronat, Ana M Wägner, Leticia Rodríguez-Rodríguez, Pedro De Pablos-Velasco, Ignacio Llorente Gómez De Segura, Himar González- Pacheco, Montserrat Carmona Rodríguez, Pedro Serrano-Aguilar, Indica Team. Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial. JMIR mHealth and uHealth. 2020; 8 (11):e18922.
Chicago/Turabian StyleYolanda Ramallo-Fariña; Miguel Angel García-Bello; Lidia García-Pérez; Mauro Boronat; Ana M Wägner; Leticia Rodríguez-Rodríguez; Pedro De Pablos-Velasco; Ignacio Llorente Gómez De Segura; Himar González- Pacheco; Montserrat Carmona Rodríguez; Pedro Serrano-Aguilar; Indica Team. 2020. "Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial." JMIR mHealth and uHealth 8, no. 11: e18922.
Digital health literacy (DHL) is the ability to search, understand and evaluate information from digital media and apply that knowledge to solve health problems. However, currently many citizens have not developed these skills, and this compromises not only the self-management of their health, but the possibility that health services are socially sustainable. The objective of this article was to present the objectives, activities and results of the IC-Health project whose objective was to develop a series of massive open online courses (MOOCs) to improve the DHL skills of European citizens. An exploratory report on DHL’s current evidence was developed. Furthermore, a survey, focus groups and group interviews were conducted to determine DHL levels and the needs of population cohorts (children; adolescents; pregnant and lactating women; the elderly; and people affected by type 1 and type 2 diabetes). A participation strategy with end users was designed through a community of practice for the creation of MOOCs with the seven European countries that participated in the consortium. Thirty-five MOOCs were developed in eight different languages and a descriptive and exploratory assessment of MOOCs was conducted with new participants. This first evaluation indicated that MOOCs can be an effective educational resource for DHL and a facilitator of shared decision-making processes. The process of co-creation of MOOCs, the components, the challenges and the opportunities identified in this European project could be useful for other developers of MOOCs who want to co-create interventions with beneficiaries in similar settings. Further longer-term actions are still needed to improve citizens’ DHL.
Lilisbeth Perestelo-Perez; Alezandra Torres-Castaño; Carina González-González; Yolanda Alvarez-Perez; Ana Toledo-Chavarri; Ana Wagner; Michelle Perello; Stephan Van Der Broucke; Gonzalo Díaz-Meneses; Barbara Piccini; Amado Rivero-Santana; Pedro Serrano-Aguilar; on behalf of the IC Project Consortium. IC-Health Project: Development of MOOCs to Promote Digital Health Literacy: First Results and Future Challenges. Sustainability 2020, 12, 6642 .
AMA StyleLilisbeth Perestelo-Perez, Alezandra Torres-Castaño, Carina González-González, Yolanda Alvarez-Perez, Ana Toledo-Chavarri, Ana Wagner, Michelle Perello, Stephan Van Der Broucke, Gonzalo Díaz-Meneses, Barbara Piccini, Amado Rivero-Santana, Pedro Serrano-Aguilar, on behalf of the IC Project Consortium. IC-Health Project: Development of MOOCs to Promote Digital Health Literacy: First Results and Future Challenges. Sustainability. 2020; 12 (16):6642.
Chicago/Turabian StyleLilisbeth Perestelo-Perez; Alezandra Torres-Castaño; Carina González-González; Yolanda Alvarez-Perez; Ana Toledo-Chavarri; Ana Wagner; Michelle Perello; Stephan Van Der Broucke; Gonzalo Díaz-Meneses; Barbara Piccini; Amado Rivero-Santana; Pedro Serrano-Aguilar; on behalf of the IC Project Consortium. 2020. "IC-Health Project: Development of MOOCs to Promote Digital Health Literacy: First Results and Future Challenges." Sustainability 12, no. 16: 6642.
Diabetes mellitus (DM) is the first cause of end stage chronic kidney disease (CKD). Animal models of the disease can shed light on the pathogenesis of the diabetic nephropathy (DN) and novel and earlier biomarkers of the condition may help to improve diagnosis and prognosis. This review summarizes the most important features of animal models used in the study of DN and updates the most recent progress in biomarker research.
Laura Pérez-López; Mauro Boronat; Carlos Melián; Yeray Brito-Casillas; Ana M. Wägner. Animal Models and Renal Biomarkers of Diabetic Nephropathy. Advances in Experimental Medicine and Biology 2020, 521 -551.
AMA StyleLaura Pérez-López, Mauro Boronat, Carlos Melián, Yeray Brito-Casillas, Ana M. Wägner. Animal Models and Renal Biomarkers of Diabetic Nephropathy. Advances in Experimental Medicine and Biology. 2020; ():521-551.
Chicago/Turabian StyleLaura Pérez-López; Mauro Boronat; Carlos Melián; Yeray Brito-Casillas; Ana M. Wägner. 2020. "Animal Models and Renal Biomarkers of Diabetic Nephropathy." Advances in Experimental Medicine and Biology , no. : 521-551.
BACKGROUND Type 2 diabetes mellitus (T2DM) is a chronic disease in which health outcomes are related to decision making by patients and health care professionals. OBJECTIVE This study aims to assess the effectiveness of internet-based multicomponent interventions to support decision making of all actors involved in the care of patients with T2DM in primary care. METHODS The INDICA study is an open, community-based, multicenter trial with random allocation to usual care or the intervention for patients, the intervention for health care professionals in primary care, or the combined intervention for both. In the intervention for patients, participants received an educational group program and were monitored and supported by logs, a web-based platform, and automated SMS. Those in the intervention for professionals also received an educational program, a decision support tool embedded in the electronic clinical record, and periodic feedback about patients’ results. A total of 2334 people with T2DM, regardless of glycated hemoglobin (HbA1c) levels and without diabetes-related complications, were included. The primary end point was change in HbA1c level. The main analysis was performed using multilevel mixed models. RESULTS For the overall sample, the intervention for patients attained a significant mean reduction in HbA1c levels of ‒0.27 (95% CI ‒0.45 to ‒0.10) at month 3 and ‒0.26 (95% CI ‒0.44 to ‒0.08) at month 6 compared with usual care, which remained marginally significant at month 12. A clinically relevant reduction in HbA1c level was observed in 35.6% (191/537) of patients in the intervention for patients and 26.0% (152/586) of those in usual care at month 12 (P=.006). In the combined intervention, HbA1c reduction was significant until month 18 (181/557, 32.6% vs 140/586, 23.9%; P=.009). Considering the subgroup of patients uncontrolled at baseline, all interventions produced significant reductions in HbA1c levels across the entire study period: ‒0.49 (95% CI ‒0.70 to ‒0.27) for the intervention for patients, ‒0.35 (95% CI ‒0.59 to ‒0.14) for the intervention for professionals, and ‒0.35 (95% CI ‒0.57 to ‒0.13) for the combined intervention. Differences in HbA1c for the area under the curve considering the entire period were significant for the intervention for patients and the combined intervention compared with usual care (P=.03 for both). Compared with usual care, the intervention for professionals and the combined intervention had significant longer-term reductions in systolic and diastolic blood pressure. CONCLUSIONS In uncontrolled patients, the intervention for patients at baseline provided clinically relevant and significant longer-term reductions of HbA1c levels. The intervention for professionals and combined intervention also improved the cardiovascular risk profile of patients. CLINICALTRIAL ClinicalTrials.gov NCT01657227; https://clinicaltrials.gov/ct2/show/NCT01657227
Yolanda Ramallo-Fariña; Miguel Angel García-Bello; Lidia García-Pérez; Mauro Boronat; Ana M Wägner; Leticia Rodríguez-Rodríguez; Pedro De Pablos-Velasco; Ignacio Llorente Gómez De Segura; Himar González- Pacheco; Montserrat Carmona Rodríguez; Pedro Serrano-Aguilar; Indica Team. Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial (Preprint). 2020, 1 .
AMA StyleYolanda Ramallo-Fariña, Miguel Angel García-Bello, Lidia García-Pérez, Mauro Boronat, Ana M Wägner, Leticia Rodríguez-Rodríguez, Pedro De Pablos-Velasco, Ignacio Llorente Gómez De Segura, Himar González- Pacheco, Montserrat Carmona Rodríguez, Pedro Serrano-Aguilar, Indica Team. Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial (Preprint). . 2020; ():1.
Chicago/Turabian StyleYolanda Ramallo-Fariña; Miguel Angel García-Bello; Lidia García-Pérez; Mauro Boronat; Ana M Wägner; Leticia Rodríguez-Rodríguez; Pedro De Pablos-Velasco; Ignacio Llorente Gómez De Segura; Himar González- Pacheco; Montserrat Carmona Rodríguez; Pedro Serrano-Aguilar; Indica Team. 2020. "Effectiveness of Internet-Based Multicomponent Interventions for Patients and Health Care Professionals to Improve Clinical Outcomes in Type 2 Diabetes Evaluated Through the INDICA Study: Multiarm Cluster Randomized Controlled Trial (Preprint)." , no. : 1.
BackgroundType 1 diabetes is a chronic disease with complex therapeutic recommendations that require day-to-day lifestyle changes. People with type 1 diabetes need to be involved in their health care in order to achieve satisfactory control of the condition. Motivational Interviewing is a communication tool that has been shown to be effective in changing behaviors in people with addictions, obesity and type 2 diabetes.Our objective is to evaluate the impact of a Motivational Interviewing intervention in patients with type 1 diabetes, through a randomized controlled clinical trial.MethodsSixty-six patients with type 1 diabetes and hemoglobin A1c>= 8% have been included and randomly assigned (computer-generated sequence, sealed envelopes, ratio 1:1) either to the intervention group or to the control group. In the intervention group, appointments every four months with the endocrinologist include Motivational Interviewing; in the control group, the appointments proceed as usual. Patients will be followed for 16 months.The primary outcome will be self-care behaviors, assessed according to a validated questionnaire, the Diabetes Self-Care Inventory-Revised Version. Secondary outcomes include: HbA1c, motivation for self-care, self-efficacy, health-related quality of life, satisfaction with professional-patient relationship, fulfillment of patients' own objectives and other sociodemographic and clinical variables related to disease control.The practitioners will receive training in Motivational Interviewing in order to help them promote adherence to self-care, encourage patient motivation and improve the doctor-patient relationship. The Motivational Interviewing intervention will be evaluated through videorecordings of the sessions and the administration of a purpose-built questionnaire, the EVEM 2.0 scale, by two psychologists, blinded to the assigned treatment. DiscussionThere is evidence that MI can improve self-care in type 2 diabetes. In T1D, however, its application has focused on adolescents, but, at present, there are no published data on the effect of MI in adults with T1D. In this study, we aim to evaluate the effect of MI on self-care and HbA1c.
Dacil Alvarado-Martel; Mauro Boronat; María Del Pino Alberiche; María Andrea Algara; Ana M Wägner. Motivational Interviewing and Self-care in Type 1 Diabetes:a randomized controlled clinical trial study protocol. 2020, 1 .
AMA StyleDacil Alvarado-Martel, Mauro Boronat, María Del Pino Alberiche, María Andrea Algara, Ana M Wägner. Motivational Interviewing and Self-care in Type 1 Diabetes:a randomized controlled clinical trial study protocol. . 2020; ():1.
Chicago/Turabian StyleDacil Alvarado-Martel; Mauro Boronat; María Del Pino Alberiche; María Andrea Algara; Ana M Wägner. 2020. "Motivational Interviewing and Self-care in Type 1 Diabetes:a randomized controlled clinical trial study protocol." , no. : 1.
Familial hypercholesterolemia (FH) is a monogenic disease characterized by high levels of low-density lipoprotein cholesterol and premature atherosclerotic cardiovascular disease. FH is caused by loss of function mutations in genes encoding LDL receptor (LDLR), and Apolipoprotein B (APOB) or gain of function (GOF) mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9). In this study, we identified a novel variant in PCSK9, p.(Arg499His), located in the C-terminal domain, in two unrelated FH patients from Spain and Italy. We studied familial segregation and determined variant activity in vitro. We determined PCSK9 expression, secretion and activity of the variant in transfected HEK293 cells; extracellular activity of the recombinant p.(Arg499His) PCSK9 variant in HEK 293 and HepG2 cells; PCSK9 affinity to the LDL receptor at neutral and acidic pH; the mechanism of action of the p.(Arg499His) PCSK9 variant by co-transfection with a soluble construct of the LDL receptor and by determining total PCSK9 intracellular accumulation when endosomal acidification is impaired and when an excess of soluble LDLr is present in the culture medium. Our results show high LDL-C concentrations and FH phenotype in p.(Arg499His) carriers. In vitro functional characterization shows that p.(Arg499His) PCSK9 variant causes a reduction in LDLr expression and LDL uptake. An intracellular activity for this variant is also shown when blocking the activity of secreted PCSK9 and by inhibiting endosomal acidification. We demonstrated that p.(Arg499His) PCSK9 variant causes a direct intracellular degradation of LDLr therefore causing FH by reducing LDLr availability.
Rosa M. Sánchez-Hernández; Maria Donata Di Taranto; Asier Benito-Vicente; Kepa B. Uribe; Itziar Lamiquiz-Moneo; Asier Larrea-Sebal; Shifa Jebari; Unai Galicia-Garcia; F. Javier Nóvoa; Mauro Boronat; Ana M. Wägner; Fernando Civeira; César Martín; Giuliana Fortunato. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis 2019, 289, 162 -172.
AMA StyleRosa M. Sánchez-Hernández, Maria Donata Di Taranto, Asier Benito-Vicente, Kepa B. Uribe, Itziar Lamiquiz-Moneo, Asier Larrea-Sebal, Shifa Jebari, Unai Galicia-Garcia, F. Javier Nóvoa, Mauro Boronat, Ana M. Wägner, Fernando Civeira, César Martín, Giuliana Fortunato. The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis. 2019; 289 ():162-172.
Chicago/Turabian StyleRosa M. Sánchez-Hernández; Maria Donata Di Taranto; Asier Benito-Vicente; Kepa B. Uribe; Itziar Lamiquiz-Moneo; Asier Larrea-Sebal; Shifa Jebari; Unai Galicia-Garcia; F. Javier Nóvoa; Mauro Boronat; Ana M. Wägner; Fernando Civeira; César Martín; Giuliana Fortunato. 2019. "The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9." Atherosclerosis 289, no. : 162-172.
Aim To evaluate the effects of Alimentación Normal con Ajuste de Insulina (ANAIS), a group‐based, therapeutic education programme for Type 1 diabetes based on a flexible insulin regimen adjusted to the individual's food intake. Methods Participants with Type 1 diabetes and HbA1c levels of 53–86 mmol/mol (7–10%) were recruited from outpatient clinics at a tertiary care centre. They were randomized (using opaque, sealed envelopes, with a 2:1 treatment allocation ratio) to attend the training course immediately (immediate ANAIS; intervention group) or a year later (delayed ANAIS; control group). The main outcome was HbA1c level at 1 year. Secondary outcomes included lipid levels, weight, hypoglycaemic events, insulin dose, treatment satisfaction, self‐perceived dietary freedom, quality of life and participant‐defined goals. Results A total of 48 participants were assigned to the intervention group and 32 to the control group. Twelve months after completing the training, adjusted HbA1c was not significantly different in the intervention group [64 ± 1.3 vs 68 ± 1.6 mmol/mol (8.0 ±0.1% vs 8.4 ±0.1%); P=0.081]. Treatment satisfaction was significantly higher in the intervention group, but no differences were found in hypoglycaemic events, weight, insulin dose or changes in dietary freedom. At 1 year after the intervention, 72% of the participants (vs 33% in the control group; P=0.046) reported exceeding their expectations regarding achievement of their main personal goal. Conclusion Promoting dietary freedom and empowering people with Type 1 diabetes through structured education programmes, such as ANAIS, improves treatment satisfaction and self‐defined goals. No significant improvement in HbA1c level was achieved.
R. M. Sánchez‐Hernández; D. Alvarado‐Martel; Y. López‐Plasencia; A. Carrillo‐Domínguez; A. Jiménez‐Rodríguez; J. Rodríguez‐Cordero; T. Vera-Elzo; Á. Santana Del Pino; F. J. Nóvoa‐Mogollón; A. M. Wägner. Assessment of Alimentación Normal con Ajuste de Insulina (ANAIS), a Spanish version of the DAFNE programme, in people with Type 1 diabetes: a randomized controlled parallel trial. Diabetic Medicine 2019, 36, 1037 -1045.
AMA StyleR. M. Sánchez‐Hernández, D. Alvarado‐Martel, Y. López‐Plasencia, A. Carrillo‐Domínguez, A. Jiménez‐Rodríguez, J. Rodríguez‐Cordero, T. Vera-Elzo, Á. Santana Del Pino, F. J. Nóvoa‐Mogollón, A. M. Wägner. Assessment of Alimentación Normal con Ajuste de Insulina (ANAIS), a Spanish version of the DAFNE programme, in people with Type 1 diabetes: a randomized controlled parallel trial. Diabetic Medicine. 2019; 36 (8):1037-1045.
Chicago/Turabian StyleR. M. Sánchez‐Hernández; D. Alvarado‐Martel; Y. López‐Plasencia; A. Carrillo‐Domínguez; A. Jiménez‐Rodríguez; J. Rodríguez‐Cordero; T. Vera-Elzo; Á. Santana Del Pino; F. J. Nóvoa‐Mogollón; A. M. Wägner. 2019. "Assessment of Alimentación Normal con Ajuste de Insulina (ANAIS), a Spanish version of the DAFNE programme, in people with Type 1 diabetes: a randomized controlled parallel trial." Diabetic Medicine 36, no. 8: 1037-1045.
Genetic diagnosis of familial hypercholesterolemia (FH) has not been universally performed in the Canary Islands (Spain). This study aimed to genetically characterize a cohort of patients with FH in the island of Gran Canaria. Study subjects were 70 unrelated index cases attending a tertiary hospital in Gran Canaria, with a clinical diagnosis of FH, according to the criteria of the Dutch Lipid Clinic Network. Given that 7 of the first 10 cases with positive genetic study were carriers of a single mutation in LDLR gene [p.(Tyr400_Phe402del)], a specific PCR-based assay was developed for the detection of this variant as a first screening step on the remaining subjects. In those without this mutation, molecular diagnosis was completed using a next generation sequencing panel including LDLR, APOB, PCSK9, LDLRAP1, APOE, STAP1 and LIPA genes, and incorporating copy number variation detection in LDLR. On the whole, 44 subjects (62%) had a positive genetic study, of whom 30 (68%) were heterozygous carriers of the p.(Tyr400_Phe402del) variant. Eleven subjects carried other mutations in LDLR, including the novel mutation NM_000527.4: c.877dupG; NP_000518.1: p.(Asp293Glyfs*8). An unclassified PCSK9 gene variant was found in one subject [(NM_174936.3:c.1496G>A; NP_777596.2: p.(Arg499His)]. Other single patients had mutations in APOB (heterozygous), and in LIPA (homozygous). All identified variants co-segregated with the disease phenotype. These findings suggest a founder effect for the p.(Tyr400_Phe402del) LDLR mutation in Gran Canaria. A cost-effective local screening strategy for genetic diagnosis of FH could be implemented in this region.
Rosa M. Sánchez-Hernández; Antonio Tugores; Francisco J. Nóvoa; Yeray Brito-Casillas; Ana B. Expósito-Montesdeoca; Paloma Garay; Ana M. Bea; Marta Riaño; Miguel Pocovi; Fernando Civeira; Ana M. Wägner; Mauro Boronat. The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. Journal of Clinical Lipidology 2019, 13, 618 -626.
AMA StyleRosa M. Sánchez-Hernández, Antonio Tugores, Francisco J. Nóvoa, Yeray Brito-Casillas, Ana B. Expósito-Montesdeoca, Paloma Garay, Ana M. Bea, Marta Riaño, Miguel Pocovi, Fernando Civeira, Ana M. Wägner, Mauro Boronat. The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia. Journal of Clinical Lipidology. 2019; 13 (4):618-626.
Chicago/Turabian StyleRosa M. Sánchez-Hernández; Antonio Tugores; Francisco J. Nóvoa; Yeray Brito-Casillas; Ana B. Expósito-Montesdeoca; Paloma Garay; Ana M. Bea; Marta Riaño; Miguel Pocovi; Fernando Civeira; Ana M. Wägner; Mauro Boronat. 2019. "The island of Gran Canaria: A genetic isolate for familial hypercholesterolemia." Journal of Clinical Lipidology 13, no. 4: 618-626.
The number of mobile applications (apps) related to health is increasing, and diabetes mellitus (DM) is not an exception. The aim of this study was to assess the free mobile applications for the management of diabetes available, in Spanish, in the Spanish market. GooglePlay (Android) and AppStore (iOS) were reviewed to identify free apps, in Spanish, aimed at people with diabetes. Their main functions and a series of quality and usability features were evaluated and scored. These scores were used to make a top list with the best apps. Out of 794 registered apps, 42 were evaluated and included in the quality assessment, while 34 apps were included in the usability assessment. The main function of most of the apps was to act as a blood glucose diary (n: 30; 71.43%). As for privacy, most of the applications (33 apps; 78.6%) access device/personal data. Only a minority of apps [3 (7.1%)] reported being based on evidence, and only 3 apps (7.1%) had a quality label. The top scored apps were: OneTouch Reveal™, Social Diabetes™, mySugr: App Diario de diabetes™, Diabetes menú™, Tactio SALUD™ and Diabetes:M™. There are few free apps for diabetes management available in Spanish, most lack quality certification and very few provide scientific references about their content. Furthermore, most of the apps access personal/device data. La cantidad de aplicaciones móviles (apps) relacionadas con la salud está aumentando, y la diabetes mellitus (DM) no es una excepción. El objetivo de este estudio es evaluar las apps móviles gratuitas disponibles en español para el manejo de la diabetes. Google Play (Android) y App Store (iOS) fueron revisados para identificar apps gratuitas, en español, dirigidas a personas con diabetes. Sus principales funciones y una serie de características de calidad y usabilidad fueron evaluadas y calificadas. Estas puntuaciones se usaron para hacer una lista de las mejores apps. De las 794 apps registradas, 42 fueron incluidas en la evaluación de calidad, mientras que 34 apps se incluyeron en la evaluación de usabilidad. La función principal de la mayoría de las apps era actuar como un diario de glucosa en sangre (n: 30; 71,43%). En cuanto a la privacidad, la mayoría de las apps (33 apps, 78,6%) acceden a datos del dispositivo/personales. Solo una minoría de apps (3 [7,1%]) informaron que se basaban en evidencia científica y solo 3 apps (7,1%) tenían un certificado de calidad. Las apps mejor puntuadas fueron: OneTouch Reveal®, SocialDiabetes, mySugr: app Diario de diabetes®, Diabetes menú®, Tactio SALUD® y Diabetes:M®. Hay pocas apps gratuitas disponibles en español para el manejo de la diabetes, la mayoría carecen de certificado de calidad, y muy pocas proporcionan referencias científicas sobre su contenido. Asimismo, la mayoría de las apps acceden a datos del dispositivo/personales.
Adrián Quevedo Rodríguez; Ana M. Wägner. Mobile phone applications for diabetes management: A systematic review. Endocrinología, Diabetes y Nutrición (English ed.) 2019, 66, 330 -337.
AMA StyleAdrián Quevedo Rodríguez, Ana M. Wägner. Mobile phone applications for diabetes management: A systematic review. Endocrinología, Diabetes y Nutrición (English ed.). 2019; 66 (5):330-337.
Chicago/Turabian StyleAdrián Quevedo Rodríguez; Ana M. Wägner. 2019. "Mobile phone applications for diabetes management: A systematic review." Endocrinología, Diabetes y Nutrición (English ed.) 66, no. 5: 330-337.
The number of mobile applications (apps) related to health is increasing, and diabetes mellitus (DM) is not an exception. The aim of this study was to assess the free mobile applications for the management of diabetes available, in Spanish, in the Spanish market. GooglePlay (Android) and AppStore (iOS) were reviewed to identify free apps, in Spanish, aimed at people with diabetes. Their main functions and a series of quality and usability features were evaluated and scored. These scores were used to make a top list with the best apps. Out of 794 registered apps, 42 were evaluated and included in the quality assessment, while 34 apps were included in the usability assessment. The main function of most of the apps was to act as a blood glucose diary (n: 30; 71.43%). As for privacy, most of the applications (33 apps; 78.6%) access device/personal data. Only a minority of apps [3 (7.1%)] reported being based on evidence, and only 3 apps (7.1%) had a quality label. The top scored apps were: OneTouch Reveal™, Social Diabetes™, mySugr: App Diario de diabetes™, Diabetes menú™, Tactio SALUD™ and Diabetes:M™. There are few free apps for diabetes management available in Spanish, most lack quality certification and very few provide scientific references about their content. Furthermore, most of the apps access personal/device data. La cantidad de aplicaciones móviles (apps) relacionadas con la salud está aumentando, y la diabetes mellitus (DM) no es una excepción. El objetivo de este estudio es evaluar las apps móviles gratuitas disponibles en español para el manejo de la diabetes. Google Play (Android) y App Store (iOS) fueron revisados para identificar apps gratuitas, en español, dirigidas a personas con diabetes. Sus principales funciones y una serie de características de calidad y usabilidad fueron evaluadas y calificadas. Estas puntuaciones se usaron para hacer una lista de las mejores apps. De las 794 apps registradas, 42 fueron incluidas en la evaluación de calidad, mientras que 34 apps se incluyeron en la evaluación de usabilidad. La función principal de la mayoría de las apps era actuar como un diario de glucosa en sangre (n: 30; 71,43%). En cuanto a la privacidad, la mayoría de las apps (33 apps, 78,6%) acceden a datos del dispositivo/personales. Solo una minoría de apps (3 [7,1%]) informaron que se basaban en evidencia científica y solo 3 apps (7,1%) tenían un certificado de calidad. Las apps mejor puntuadas fueron: OneTouch Reveal®, SocialDiabetes, mySugr: app Diario de diabetes®, Diabetes menú®, Tactio SALUD® y Diabetes:M®. Hay pocas apps gratuitas disponibles en español para el manejo de la diabetes, la mayoría carecen de certificado de calidad, y muy pocas proporcionan referencias científicas sobre su contenido. Asimismo, la mayoría de las apps acceden a datos del dispositivo/personales.
Adrián Quevedo Rodríguez; Ana M. Wägner. Mobile phone applications for diabetes management: A systematic review. Endocrinología, Diabetes y Nutrición 2019, 66, 330 -337.
AMA StyleAdrián Quevedo Rodríguez, Ana M. Wägner. Mobile phone applications for diabetes management: A systematic review. Endocrinología, Diabetes y Nutrición. 2019; 66 (5):330-337.
Chicago/Turabian StyleAdrián Quevedo Rodríguez; Ana M. Wägner. 2019. "Mobile phone applications for diabetes management: A systematic review." Endocrinología, Diabetes y Nutrición 66, no. 5: 330-337.
Maternal diabetes is associated with an increased risk of complications for the mother and her offspring. The latter have an increased risk of foetal macrosomia, hypoglycaemia, respiratory distress syndrome, preterm delivery, malformations and mortality but also of life-long development of obesity and diabetes. Epigenetics have been proposed as an explanation for this long-term risk, and microRNAs (miRNAs) may play a role, both in short- and long-term outcomes. Gestation is associated with increasing maternal insulin resistance, as well as β-cell expansion, to account for the increased insulin needs and studies performed in pregnant rats support a role of miRNAs in this expansion. Furthermore, several miRNAs are involved in pancreatic embryonic development. On the other hand, maternal diabetes is associated with changes in miRNA both in maternal and in foetal tissues. This review aims to summarise the existing knowledge on miRNAs in gestational and pre-gestational diabetes, both as diagnostic biomarkers and as mechanistic players, in the development of gestational diabetes itself and also of short- and long-term complications for the mother and her offspring.
Adriana Ibarra; Begoña Vega-Guedes; Yeray Brito-Casillas; Ana M. Wägner. Diabetes in Pregnancy and MicroRNAs: Promises and Limitations in Their Clinical Application. Non-Coding RNA 2018, 4, 32 .
AMA StyleAdriana Ibarra, Begoña Vega-Guedes, Yeray Brito-Casillas, Ana M. Wägner. Diabetes in Pregnancy and MicroRNAs: Promises and Limitations in Their Clinical Application. Non-Coding RNA. 2018; 4 (4):32.
Chicago/Turabian StyleAdriana Ibarra; Begoña Vega-Guedes; Yeray Brito-Casillas; Ana M. Wägner. 2018. "Diabetes in Pregnancy and MicroRNAs: Promises and Limitations in Their Clinical Application." Non-Coding RNA 4, no. 4: 32.
To assess the effect of the GLP-1 analogue liraglutide on measures of cardiac function and physical performance in patients with type 2 diabetes (T2D). In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7–10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liraglutide 1.8 mg/day or a placebo for 6 months. The primary endpoint was maximum oxygen consumption (VO2max) during cycle ergometry, while other procedures included a 6-min walk test, echocardiography, anthropometry and blood tests. Safety endpoints were also monitored, and an intention-to-treat analysis was performed. A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo. There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months. HbA1c was lower (6.7% vs. 7.7%; P = 0.005), with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study. There were no severe adverse events. In this trial, liraglutide improved glycaemic control in T2D, but had no significant effects on either physical performance or myocardial function.
A.M. Wägner; G. Miranda-Calderín; M.A. Ugarte-Lopetegui; H. Marrero-Santiago; L. Suárez-Castellano; M.J. López-Madrazo; M.P. Alberiche-Ruano; N. Abselam Ahmed; C. Alemán; A. Castellot-Martín; A. Díez del Pino; F.J. Nóvoa-Mogollón. Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). Diabetes & Metabolism 2018, 45, 268 -275.
AMA StyleA.M. Wägner, G. Miranda-Calderín, M.A. Ugarte-Lopetegui, H. Marrero-Santiago, L. Suárez-Castellano, M.J. López-Madrazo, M.P. Alberiche-Ruano, N. Abselam Ahmed, C. Alemán, A. Castellot-Martín, A. Díez del Pino, F.J. Nóvoa-Mogollón. Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2). Diabetes & Metabolism. 2018; 45 (3):268-275.
Chicago/Turabian StyleA.M. Wägner; G. Miranda-Calderín; M.A. Ugarte-Lopetegui; H. Marrero-Santiago; L. Suárez-Castellano; M.J. López-Madrazo; M.P. Alberiche-Ruano; N. Abselam Ahmed; C. Alemán; A. Castellot-Martín; A. Díez del Pino; F.J. Nóvoa-Mogollón. 2018. "Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)." Diabetes & Metabolism 45, no. 3: 268-275.
Shaila Carrasco Falcón; Begoña Vega Guedes; Dácil Alvarado-Martel; Ana M. Wägner. Preconception care in diabetes: Predisposing factors and barriers. Endocrinología, Diabetes y Nutrición (English ed.) 2018, 65, 164 -171.
AMA StyleShaila Carrasco Falcón, Begoña Vega Guedes, Dácil Alvarado-Martel, Ana M. Wägner. Preconception care in diabetes: Predisposing factors and barriers. Endocrinología, Diabetes y Nutrición (English ed.). 2018; 65 (3):164-171.
Chicago/Turabian StyleShaila Carrasco Falcón; Begoña Vega Guedes; Dácil Alvarado-Martel; Ana M. Wägner. 2018. "Preconception care in diabetes: Predisposing factors and barriers." Endocrinología, Diabetes y Nutrición (English ed.) 65, no. 3: 164-171.
El control preconcepcional ha demostrado reducir el riesgo del embarazo asociado a la diabetes, pero muchas mujeres siguen quedando gestantes sin planificación previa. Nuestro objetivo fue identificar los factores predisponentes y las barreras relacionadas con la realización de control preconcepcional. Se incluyeron, de forma consecutiva, 50 mujeres con diabetes pregestacional (28 tipo 1) y 50 gestantes sin diabetes que acudían a nuestro centro. Se les pidió que cumplimentaran un cuestionario y se revisaron sus historias clínicas. Las 33 pacientes con diabetes y control preconcepcional tenían una edad actual (34,3 ± 5,3 años) y al diagnóstico de la diabetes (20,3 ± 11,3 años) similares a las 17 pacientes sin control (31,8 ± 5,3 y 19,1 ± 10,6 años, respectivamente; p > 0,1), pero estaban con más frecuencia viviendo en pareja (97% vs. 70,6%; p = 0,014), laboralmente activas (69,7% vs. 29,4%; p = 0,047), eran seguidas por un/a endocrinólogo/a (80,6% vs. 50%; p = 0,034), habían tenido abortos previos (78,6% vs. 10%; p = 0,001), y conocían la repercusión de la diabetes en el embarazo (87,5% vs. 58,8%; p = 0,029). No hubo diferencias significativas en la toma de ácido fólico pregestacional entre las gestantes con y sin diabetes (23,8% vs. 32%; p > 0,1). En las pacientes con diabetes, acudir a control preconcepcional se asoció con vivir en pareja, estar laboralmente activas, conocer el riesgo de complicaciones, tener abortos previos y ser seguidas por un/a endocrinólogo/a. Existe un bajo porcentaje de preparación de la gestación, también en el grupo sin diabetes. Preconception care has been shown to decrease the risk of pregnancy-related complications in women with diabetes, but many women do not plan their pregnancies. Our aim was to identify the associated factors and barriers related to involvement of these women in preconception care. Fifty women with pregestational diabetes (28 with type 1 diabetes) and 50 non-diabetic pregnant women were consecutively enrolled at our hospital. They completed a questionnaire, and their medical histories were reviewed. All 33 patients with diabetes who received preconception care had a similar current age (34.3 ± 5.3 years) and age at diagnosis (20.3 ± 11.3) than those with no preconception care (n = 17) (31.8 ± 5.3 and 19.1 ± 10.6 years respectively; P > .1), but were more frequently living with their partners (97% vs. 70.6%; P = .014), employed (69.7% vs. 29.4%; P = .047), and monitored by an endocrinologist (80.6% vs. 50%; P = .034), had more commonly had previous miscarriages (78.6% vs. 10%; P = .001), and knew the impact of diabetes on pregnancy (87.5% vs. 58.8%; P = .029). The frequency of preconceptional folic acid intake was similar in pregnant women with and without diabetes (23.8% vs. 32%; P > .1). Preconception care of diabetic patients is associated to living with a partner, being employed, knowing the risks of pregnancy-related complications, having previous miscarriages, and being monitored by an endocrinologist. Pregnancy planning is infrequent in both women with and without diabetes.
Shaila Carrasco Falcón; Begoña Vega Guedes; Dácil Alvarado-Martel; Ana M. Wägner. Control preconcepcional en la diabetes: factores predisponentes y barreras. Endocrinología, Diabetes y Nutrición 2018, 65, 164 -171.
AMA StyleShaila Carrasco Falcón, Begoña Vega Guedes, Dácil Alvarado-Martel, Ana M. Wägner. Control preconcepcional en la diabetes: factores predisponentes y barreras. Endocrinología, Diabetes y Nutrición. 2018; 65 (3):164-171.
Chicago/Turabian StyleShaila Carrasco Falcón; Begoña Vega Guedes; Dácil Alvarado-Martel; Ana M. Wägner. 2018. "Control preconcepcional en la diabetes: factores predisponentes y barreras." Endocrinología, Diabetes y Nutrición 65, no. 3: 164-171.
Dácil Alvarado-Martel; M. Ángeles Ruiz Fernández; Ana M. Wägner. ViDa1: un nuevo cuestionario para medir calidad de vida relacionada con la salud en la diabetes tipo 1. Endocrinología, Diabetes y Nutrición 2017, 64, 506 -509.
AMA StyleDácil Alvarado-Martel, M. Ángeles Ruiz Fernández, Ana M. Wägner. ViDa1: un nuevo cuestionario para medir calidad de vida relacionada con la salud en la diabetes tipo 1. Endocrinología, Diabetes y Nutrición. 2017; 64 (9):506-509.
Chicago/Turabian StyleDácil Alvarado-Martel; M. Ángeles Ruiz Fernández; Ana M. Wägner. 2017. "ViDa1: un nuevo cuestionario para medir calidad de vida relacionada con la salud en la diabetes tipo 1." Endocrinología, Diabetes y Nutrición 64, no. 9: 506-509.
Dácil Alvarado-Martel; M. Ángeles Ruiz Fernández; Ana M. Wägner. ViDa1: A new questionnaire for measuring health-related quality of life in patients with type 1 diabetes. Endocrinología, Diabetes y Nutrición (English ed.) 2017, 64, 506 -509.
AMA StyleDácil Alvarado-Martel, M. Ángeles Ruiz Fernández, Ana M. Wägner. ViDa1: A new questionnaire for measuring health-related quality of life in patients with type 1 diabetes. Endocrinología, Diabetes y Nutrición (English ed.). 2017; 64 (9):506-509.
Chicago/Turabian StyleDácil Alvarado-Martel; M. Ángeles Ruiz Fernández; Ana M. Wägner. 2017. "ViDa1: A new questionnaire for measuring health-related quality of life in patients with type 1 diabetes." Endocrinología, Diabetes y Nutrición (English ed.) 64, no. 9: 506-509.
A zoonotic, opportunistic out-break of tropical rat mite Ornithonyssus bacoti [Acari: Macronyssidae; Ornithonyssus bacoti (Hirst)] in an animal facility, is described. Immunocompetent mice [Mus musculus (Linnaeus)] and rat [Rattus norvegicus (Berkenhout)] strains in a conventional health status facility suffered from scratching and allopecia and staff members suffered from pruritic, erythemato-papular lesions, presumed to be allergic in origin. O. bacoti was identified and treatment with a 0.1% ivermectin solution led to its complete erradication. Safety assessment revealed no signs of acute toxicity in any animal strain. Following this inexpensive strategy, 7 wk after the initial dose, samples were negative for the presence of acari. At the time of this report, 26 months after diagnosis, O. bacoti remains undetected.
Yeray Brito-Casillas; Mercedes Díaz-Sarmiento; Moisés García-Arencibia; Cristina Carranza; Antonio Castrillo; Leandro Fernández-Pérez; Manuel Zumbado-Peña; Jorge F González; Ana M Wägner; David Florin. Outbreak and Eradication of Tropical Rat Mite (Acari: Macronyssidae) in a European Animal Facility. Journal of Medical Entomology 2017, 55, 468 -471.
AMA StyleYeray Brito-Casillas, Mercedes Díaz-Sarmiento, Moisés García-Arencibia, Cristina Carranza, Antonio Castrillo, Leandro Fernández-Pérez, Manuel Zumbado-Peña, Jorge F González, Ana M Wägner, David Florin. Outbreak and Eradication of Tropical Rat Mite (Acari: Macronyssidae) in a European Animal Facility. Journal of Medical Entomology. 2017; 55 (2):468-471.
Chicago/Turabian StyleYeray Brito-Casillas; Mercedes Díaz-Sarmiento; Moisés García-Arencibia; Cristina Carranza; Antonio Castrillo; Leandro Fernández-Pérez; Manuel Zumbado-Peña; Jorge F González; Ana M Wägner; David Florin. 2017. "Outbreak and Eradication of Tropical Rat Mite (Acari: Macronyssidae) in a European Animal Facility." Journal of Medical Entomology 55, no. 2: 468-471.
Angelo Santana Del Pino; Nathan Medina-Rodríguez; Marta Hernández-García; Francisco J. Nóvoa-Mogollón; Ana M. Wägner. Is HLA the cause of the high incidence of type 1 diabetes in the Canary Islands? Results from the Type 1 Diabetes Genetics Consortium (T1DGC). Endocrinología, Diabetes y Nutrición (English ed.) 2017, 64, 146 -151.
AMA StyleAngelo Santana Del Pino, Nathan Medina-Rodríguez, Marta Hernández-García, Francisco J. Nóvoa-Mogollón, Ana M. Wägner. Is HLA the cause of the high incidence of type 1 diabetes in the Canary Islands? Results from the Type 1 Diabetes Genetics Consortium (T1DGC). Endocrinología, Diabetes y Nutrición (English ed.). 2017; 64 (3):146-151.
Chicago/Turabian StyleAngelo Santana Del Pino; Nathan Medina-Rodríguez; Marta Hernández-García; Francisco J. Nóvoa-Mogollón; Ana M. Wägner. 2017. "Is HLA the cause of the high incidence of type 1 diabetes in the Canary Islands? Results from the Type 1 Diabetes Genetics Consortium (T1DGC)." Endocrinología, Diabetes y Nutrición (English ed.) 64, no. 3: 146-151.